WuXi XDC Reports 90.8% Revenue Surge, Expanding in ADC Market
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA...
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA...
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, backed by RTW Investments, has formed a...
WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary...
Shanghai-based kidney drug developer SanReno Therapeutics has entered into a partnership with WuXi STA, a...
Shanghai-based TYK Medicines has announced a partnership with WuXi STA, a subsidiary of WuXi AppTec...
China’s Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) has entered into a partnership with WuXi STA,...
China-based Hua Medicine (HKG: 2552) has announced a sales and distribution agreement with online pharma...
US-based Pasithea Therapeutics Corp. (NASDAQ: KTTA) has announced that Chinese Contract Research Organization (CRO) WuXi...
China-based WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a...
China-based Hua Medicine has announced the commercial launch of its Category 1 drug, dorzagliatin, with...
WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has announced the commencement...
WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA (SHA: 603259),...